SGMT
Sagimet Biosciences Inc. Series A Common Stock
Mentions (24Hr)
0.00% Today
Reddit Posts
Mentions
I don’t think the markets worked out the potential value of SGMT yet. Not a short term play but let’s see.
I’m so ready to see an SGMT reversal
SGMT extremely strong on the 1min chart rn
SGMT reversal could be in the cards sooner than I thought
Still surprised SGMT isn’t being talked about
GUTS, GTSC, SGMT, bought the dip on all of them. Let's see what they can do!
Maybe not enough people have picked up on the fact the company that SGMT licensed for the trial has come back with positive news today
Can anyone see the SGMT news other than stocktitan?
How’s SGMT a scam? Look at the analysts covering this shi. They are based in California but are targeting the Chinese market which is huge for acne
I don’t think the news on SGMT has spread it’s just on stock titan when I search it
SGMT that was a scary $2 profit 😳
SGMT phase 3 results news at 0600. Price Already jumped
I like SGMT. Maybe it’ll be my MU of 2026.
SGMT, unknown bio stock prob but most of its recent news are pretty positive about their research.
[https://www.stocktitan.net/news/SGMT/denifanstat-achieved-all-endpoints-in-the-treatment-of-moderate-to-41274qtwis0q.html](https://www.stocktitan.net/news/SGMT/denifanstat-achieved-all-endpoints-in-the-treatment-of-moderate-to-41274qtwis0q.html) , announced 2 min ago
$SGMT Life changing money will be made here based on competitors ETNB AKRO got paid handsomely
$SGMT Based on market cap disconnect when comparing to recent buyouts of $ETNB and $AKRO in billions.
$SGMT going to triple, $PROK can double or more $SPOR can do double to quadruple on GSK buyout
$SGMT worth 4 time more when comparing recent ETNB and AKRO deals. Huge green candle awaits
$SGMT worth north of 30 after big pharma paying billions for $AKRO and $ETNB. Magic word here is MASH
Market rotation is under way. From tech to health care. XBI perked up. SPRO SGMT PROK ready to moon.
PROK SPRO SGMT Train is leaving
PROK SPOR SGMT rocket launching
Was posting POET for last few days and now every is chasing. In SPRO SGMT PORK to go bonkers. Waiting on LAES to cool down.
While every is going gaga over poet. here is 3 likely multi bagger bios. $SGMT $PROK $SPOR
I put 5k on rocketlab on a whim a couple years ago and it took off. It took my inhibition away and i’ve been putting big buys on microcaps which i truly think are undervalue in the tune of 300-500k. I made a lot of money but you just have to be patient. I was down %60 at one point when i hade 450k on $SGMT for 4 months. Then it shot up to then bux 1X which then I sold. My next move 500k into another pharma stock $SNDX below 10 dollars and almost up 100%. Before 2024 i was just a boring etf investors… and before haters chime in most of my wealth is still in etfs. But i’ve built a nice sizable some from doing what others would call spec play. Again i would only do this if you have the fortitude to ride the tough times and you half most of your wealth protected so you dont end up losing it all!
here’s where my head’s at for aug/early sept (dates move, so DYOR): keeping an eye on IOBT after the topline P3 in melanoma, want to see follow-ups on durability/OS, plus any partner chatter and how they handle financing; CYTK for late-stage cardiomyopathy and how they pace the reg/launch story; VKTX across obesity/NASH where study design and tolerability matter more to me than headline hype; IMTX on TCR/T-cell durability and the exact wording around the registrational path; IOVA where it’s all about commercial execution and label expansions now; and SGMT as a mid-to-late NASH name where runway and phase-transition risk are front and center. i’ve been cleaning watchlists, re-reading protocols/SAPs, and tagging spots where label language could be the swing factor. also journaling each idea with simple if/then exits (e.g., approval + boxed warning = fade. clean label + no REMS = consider holding into early launch metrics). Not advice, just sharing how i’m approaching it. if you’re tracking other late-stage names or a weird PDUFA setup this month, drop it below and let’s sanity-check together.
10x baggers IPA, VIOT, ABAT, AMPX, SGMT, OVID 100%+/month proven on these. Great scoring on TipRanks
SGMT if their trials prove cure for specific cancer, highest analyst upside on TipRanks of all stocks with perfect 10 rating, high risk highest reward Dark horse that deserves mention is INOD. Small cap already contracted with 5 of the MAG 7. Critical for AI. Insane it never gets mentioned.
SGMT scheduled for some announcements today, already up 10% in premarket
This Yahoo article was actually from Simply Wall St - and the actual stocks it highlights is ELTP (one i've been highlighting for a few years now as they grow), SGMT, and LQMT. Did you not read the article in your link? It literally highlights 3 stocks in there...
SGMT looks poised for a rocket ship or a diarrhoea explosion downwards.
Thanks, man! I’m mostly eyeing SGMT, IMTX, IOVA, CYTK, VKTX, and a few others further down the list. I’m keeping it to high-PoA plays, hedge-fund favorites, and SMID caps with at least \~15 months of cash. Always happy to chat - drop me a DM anytime!
If you had to choose one over the other what’s your choice? I think SGMT has genuinely stronger fundamentals to give it a better shot… but fundamentals don’t mean jack shit sometimes. I’m curious to see short interest for STSS. Looks so similar to SUNE.
>*To make things worse, after one of the stocks rose quite consistently, I bought in and it ended up dumping even though the catalysts were all there (SGMT, I’m still holding btw)*
Consider stocks near consolidation or recent dips; look for undervalued setups like SGMT or OSTX.
SGMT’s 30% jump likely reflects speculative buying or news; Oppenheimer targets don’t guarantee immediate movement.
Re-reading your reply. SGMT C-Suite very transparent about the need to have their Phase 3 program fully funded by the end of the year. Given its 34% increase in share price thus far today, perhaps the funding has been secured, and that is why the SP is headed up, because 1 Oppenheimer analysis should not propel the SP like this. Meanwhile SGMT does have $188 m in cash sufficient to run its operations, as well as commence a phase 1 trial in severe acne if the phase 3 in China is positive. Acne far cheaper to run trials vs. MASH.
Who else missed out on the massive spike in SGMT arrrghhh
Good info! From what I’ve read, Sagimet might pull off what others couldn’t since its drug works differently. No other company has advanced FASN inhibitors into clinical trials for MASH treatment. Oppenheimer seems to think there’s a solid chance, and if they succeed, this could be a $20 stock even before receiving approval. In fact, SGMT already jumped to $20 in January based on positive topline results from their phase 2b trial.
That was a very detailed write-up. Thank you. I day trade the news most mornings, and I remember when the press release on TN-201 was issued. I’m almost certain I traded it, but - since I can’t recall for certain - I must have not gained or lost much. In addition to day trading, I sometimes buy and long-term hold stocks for potential breakthrough therapeutics like this. Here’s my criteria that influences that choice: Occasionally (perhaps once or twice a month) the news is so good that I buy in on the same day the news is released. An example of this would be SGMO. On Oct 22nd, a press release was issued saying the FDA was going to accelerate approval of SGMO’s gene therapy drug because the phase 2 trials were so promising. I bought in near the end of the day in the low $1.20s. The stock has done well, and I don’t forget to take profits. Another example of this is SGMT. On Oct 1st, they issued a press release stating the FDA had granted a “breakthrough therapy designation” to one of their drug candidates. I went in hard on this one at an avg just above $3 and it has done well. Much more common than these FDA pronouncements (and by more common I mean they happen several times a week instead of once or twice a month) are press releases about promising phase 1/2 studies or cohort studies. These are a crap shoot in my opinion - as likely to go down as they are up. While they’re ok to day trade, I don’t look to get in and hold until I’ve seen some market guidance. It’s often the second day - the day after the press release is issued - that tells the tail. If it closes green, I’m cautiously interested. If it closes red, I lose interest quick. TYNA failed this test, so I moved on and forgot about it. Your write-up is interesting and caused me to give it a second look. I remember at the time I read the press release I thought this stock has the potential to be gold mine, but the probability of that is low. Seeing the list of institutional investors is promising, but that big red candle on the day after the news broke is serious red flag for me. The fact that it has fallen even further than that after 2 weeks makes it a no go for me at this time. I’d need to see new news on it before jumping in. I realize I may be missing out on a millionaire-maker stock, but the probability of that happening is too low for a cautious man like me. I wish you great success with it, tho. To the moon! I’d like to thank you again for this write-up and encourage you to do more. I find it fascinating. Great job!